<html>
<head>
<META http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>NCT00004500 on 2005_06_23: ClinicalTrials.gov Archive</title>
<link rel="stylesheet" href="/archive/history.css">
<link rel="stylesheet" href="/archive/received.css">
</head>
<body class="received">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="navLinks" class="navLinks"><a href="/archive/NCT00004500">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00004500">&#8593; Current version of this study</a></div><h1>View of NCT00004500 on
  2005_06_23</h1>
<table class="info">
<tr>
<th nowrap>ClinicalTrials Identifier:</th><td>NCT00004500</td>
</tr>
<tr>
<th>Updated:</th><td>2005_06_23</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p></p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>OBJECTIVES:<br>
<br>I. &nbsp;Determine the safety and efficacy of lucinactant in full term newborn infants with meconium aspiration syndrome.</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>PROTOCOL OUTLINE:<br>
<br>This is a randomized, multicenter study. Patients are randomized to one of two treatment arms.<br>
<br>Arm I: Patients receive lucinactant by bronchoalveolar lavage, into the right and left lung, followed by lung drainage. Treatment repeats when patient stabilizes or every 15 minutes for 2 courses.<br>
<br>Arm II: Patients receive standard treatment including oxygen, conventional mechanical ventilation, sedation, paralysis, vasopressors, and alkalinization.<br>
<br>Patients are followed for 12 months.</p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 3</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Treatment</td>
</tr>
<tr>
<th>Study design</th><td>Randomized</td>
</tr>
<tr>
<th>Study design</th><td>Active Control</td>
</tr>
<tr>
<th>Study design</th><td>Single Group Assignment</td>
</tr>
<tr>
<th>Study design</th><td>Safety/Efficacy Study</td>
</tr>
<tr>
<th>Condition</th><td>
         Meconium Aspiration
      </td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: Lucinactant</div>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>
            Recruiting
         </td>
</tr>
<tr>
<th>Start date</th><td>
         2000-11
      </td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>PROTOCOL ENTRY CRITERIA:<br>
<br>--Disease Characteristics--<br>
<br>Diagnosis of meconium aspiration syndrome with respiratory distress and meconium staining at birth, in airways, or in bronchial secretions, in which there is no other major cause for respiratory distress<br>
<br>Conventional intermittent mandatory ventilation<br>
<br>At least 37 weeks gestational age<br>
<br>--Patient Characteristics--<br>
<br>Renal: No oligohydramnios with renal dysgenesis<br>
<br>Cardiovascular: No congenital cyanotic heart disease<br>
<br>Pulmonary: No airway anomalies; No lung hypoplasia; No pulmonary hemorrhage; No pulmonary interstitial emphysema, uncontrollable air leaks, pneumothorax, pneumomediastinum, or pneumopericardium; Oxygenation index at least 5 and no greater than 30 on a single arterial blood gas reading within 60 minutes prior to study; No diaphragmatic hernia<br>
<br>Neurologic: No known grade III or IV intraventricular hemorrhage; No obvious CNS abnormalities or malformations<br>
<br>Other: No hydrops fetalis immune and nonimmune; No prolonged (at least 3 weeks) rupture of the fetal membranes</p>
</td>
</tr>
<tr>
<th>Gender</th><td>
            Both
         </td>
</tr>
<tr>
<th>Minimum age</th><td>N/A</td>
</tr>
<tr>
<th>Maximum age</th><td>2 Days</td>
</tr>
<tr>
<th>Healthy volunteers</th><td>No</td>
</tr>
<tr>
<th>Expected enrollment</th><td>200</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>FDA Office of Orphan Products Development</td>
</tr>
<tr>
<th>Organization study ID</th><td>199/14367</td>
</tr>
<tr>
<th>Secondary ID</th><td>
            ATI-FDR001424
         </td>
</tr>
<tr>
<th>Sponsor</th><td>
               FDA Office of Orphan Products Development
            </td>
</tr>
<tr>
<th>Collaborator</th><td>
               Discovery Laboratories
            </td>
</tr>
<tr>
<th>Health Authority</th><td>
               United States: Federal Government
         </td>
</tr>
</table><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div></body>
</html>
